Agios Pharmaceuticals, Inc. Stock price

Equities

AGIO

US00847X1046

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
29.29 USD -2.17% Intraday chart for Agios Pharmaceuticals, Inc. -4.90% +31.52%
Sales 2024 * 64.29M Sales 2025 * 115M Capitalization 1.65B
Net income 2024 * -317M Net income 2025 * -360M EV / Sales 2024 * 24.5 x
Net cash position 2024 * 68.82M Net Debt 2025 * 36.47M EV / Sales 2025 * 14.7 x
P/E ratio 2024 *
-5.36 x
P/E ratio 2025 *
-4.99 x
Employees 385
Yield 2024 *
-
Yield 2025 *
-
Free-Float 76.03%
More Fundamentals * Assessed data
Dynamic Chart
RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises MT
Transcript : Agios Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Agios Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing MT
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio CI
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints MT
Agios' blood disorder drug meets goals of late-stage study RE
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia CI
Transcript : Agios Pharmaceuticals, Inc. - Special Call
Transcript : Agios Pharmaceuticals, Inc. - Special Call
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition CI
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes CI
More news
1 day-2.17%
1 week-4.90%
Current month-9.38%
1 month+10.49%
3 months+25.98%
6 months+15.04%
Current year+31.52%
More quotes
1 week
28.94
Extreme 28.94
31.04
1 month
26.19
Extreme 26.19
35.50
Current year
20.96
Extreme 20.96
35.50
1 year
19.80
Extreme 19.795
35.50
3 years
16.75
Extreme 16.75
62.16
5 years
16.75
Extreme 16.75
68.89
10 years
16.75
Extreme 16.75
138.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 22-08-07
Director of Finance/CFO 49 22-09-25
Chairman 62 17-12-04
Members of the board TitleAgeSince
Director/Board Member 69 23-05-31
Director/Board Member 64 14-12-08
Director/Board Member 71 15-06-22
More insiders
Date Price Change Volume
24-03-18 29.29 -2.17% 654,650
24-03-15 29.94 +1.63% 1,340,994
24-03-14 29.46 -1.80% 539,440
24-03-13 30 -0.96% 518,166
24-03-12 30.29 -1.66% 518,058

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (LR MDS), and hemolytic anemias.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
29.29 USD
Average target price
40.67 USD
Spread / Average Target
+38.84%
Consensus
  1. Stock
  2. Equities
  3. Stock Agios Pharmaceuticals, Inc. - Nasdaq